This episode examines pharmacologic strategies used to treat protozoal and helminth infections. Drawing from Murray’s Chapter 71, it explores how antiparasitic therapy must account for organism complexity, life cycle stage, and host toxicity.
Unlike bacteria, parasites are eukaryotic and often multicellular. This limits therapeutic selectivity and requires targeting unique metabolic pathways or structural vulnerabilities.
Major drug classes include:
Antimalarials (e.g., chloroquine, artemisinin-based therapies)
Antiprotozoals (e.g., metronidazole, nitazoxanide)
Antihelminthics (e.g., albendazole, mebendazole, ivermectin, praziquantel)
Drug choice depends on:
Parasite species
Life cycle stage
Tissue location
Host immune status
Resistance patterns and geographic variation influence therapy selection, particularly in malaria.
Conceptually, antiparasitic therapy demands ecological awareness - drugs must intersect precisely with parasite biology without overwhelming host physiology.
Key Takeaways
Parasites are eukaryotic, limiting drug selectivity
Treatment depends on life cycle stage
Albendazole and praziquantel are key antihelminthics
Artemisinin combinations are central in malaria therapy
Geographic resistance patterns guide drug choice
